

CD25 / IL-2R α Ab -4 (Clone 4C9)

Mouse Monoclonal Antibody

Cat. #MS-1088-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant)

Cat. #MS-1088-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)

Cat. #MS-1088-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective December 9, 2011

Description: IL-2R (T-cell growth factor receptor) consists of a chain of 55kDa (also known as Tac antigen or p55 or α chain) and a p75 or β chain. IL-2R α is over-expressed on the surface of activated T-cells, HTLV-1 or -2 positive T-cell lines, and moderately expressed on activated B-cells, NK-cells, and macrophages. CD25 molecule alone appears to function as a low affinity receptor and associates with CD122 (IL-2R β chain, p75) and CD132 (common γ chain) to form the high affinity IL-2 receptor complex

Mol. Wt. of Antigen: 55kDa

Epitope: Extracellular domain

Species Reactivity: Human. Others not-tested.

Clone Designation: 4C9

Ig Isotype: IgG_{2b}

Immunogen: Recombinant protein corresponding to the external domain of the Interleukin-2 Receptor molecule.

Application and Suggested Dilutions:

- Immunohistology (Formalin/paraffin only)
(Use Ab at 1:40-1:80 for 60 min at RT)
- * [Staining of formalin-fixed tissues REQUIRES boiling tissue sections in 10mM citrate buffer, pH 6.0, (**NEOMARKERS'** Cat. #AP-9003), for 10-20 min followed by cooling at RT for 20 min.]

The optimal dilution for a specific application should be determined by the investigator.

Positive Control: Tonsil or lymph node

Cellular Localization: Cell membrane

Supplied As:

Tissue culture supernatant with 0.09% sodium azide,
or

Prediluted antibody which is ready-to-use for staining of formalin-fixed, paraffin-embedded tissues.

Storage and Stability:

Store vial at 4°C. When stored at 2-8°C, this antibody is stable for 24 months.

Suggested References:

1. Morgan D.A., et al. (1976) Science 193: 1007.
2. Smith K.A. (1980) Immunol. Rev. 51: 337.

Limitations and Warranty:

Our products are intended FOR RESEARCH USE ONLY and are not approved for clinical diagnosis, drug use or therapeutic procedures. No products are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our data sheets and website. Our warranty is limited to the actual price paid for the product. NeoMarkers is not liable for any property damage, personal injury, time or effort or economic loss caused by our products.

Material Safety Data:

This product is not licensed or approved for administration to humans or to animals other than the experimental animals. Standard Laboratory Practices should be followed when handling this material. The chemical, physical, and toxicological properties of this material have not been thoroughly investigated. Appropriate measures should be taken to avoid skin and eye contact, inhalation, and ingestion. The material contains 0.09% sodium azide as a preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material as indicated above. The National Institute of Occupational Safety and Health has issued a bulletin citing the potential explosion hazard due to the reaction of sodium azide with copper, lead, brass, or solder in the plumbing systems. Sodium azide forms hydrazoic acid in acidic conditions and should be discarded in a large volume of running water to avoid deposits forming in metal drainage pipes.



CD25 / IL-2R α Ab -4 (Clone 4C9)

Mouse Monoclonal Antibody

Cat. #MS-1088-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant)

Cat. #MS-1088-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)

Cat. #MS-1088-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective December 9, 2011

*For Research Use Only***Additional Suggested References:**

1. Hatakeyama M. and T. Taniguchi (1990) "Interleukin 2" in Peptide Growth Factors and Their Receptors I, Sporn, M.B. and Roberts A.B., eds. Springer Verlag, New York, p. 523.
2. Taniguchi T., et al. (1983) Nature 302: 305.
3. Waldmann T.A., et al. (1984) J. Exp. Med. 160: 1450.
4. Zubler R.H., et al. (1984) J. Exp. Med. 160: 1170.
5. Henney C.S., et al. (1981) Nature 291: 335.
6. Tsudo M., et al. (1987) Proc. Natl. Acad. Sci. USA 84: 5394.
7. Trinchieri G., et al. (1984) J. Exp. Med. 160: 1147.
8. Ortaldo J.R., et al. (1984) J. Immunol. 133: 779.
9. Biron C.A., et al. (1990) J. Exp. Med. 171: 173.
10. Siegel J.P., et al. (1987) Science 238: 75.
11. Robertson M.J. and J. Ritz (1992). Chapter 12 in NK Mediated Cytotoxicity: Receptors, Signaling and Mechanisms, E. Lotsova, ed., CRC Press, Boca Raton, Fla., p. 184.
12. Shibuya A., et al. (1993) Blood 81: 1819.
13. Spagnoli G.C., et al. (1993) Cell. Immunol. 146: 391.
14. Lotze M.T., et al. (1981) Cancer Res. 41: 4420.
15. Grimm E.A., et al. (1982) J. Exp. Med. 155: 1823.
16. Swain S.L., et al. (1991) Curr. Opin. Immunol. 3: 304.
17. Djeu J.Y., et al. (1993) J. Immunol. 150: 960.
18. Malkovsky M., et al. (1987) Nature 325: 262.
19. Tsudo M., et al. (1986) Proc. Natl. Acad. Sci. USA 83: 9694.
20. Sharon M., et al. (1986) Science 234: 859.
21. Smith K.A. (1989) Annu. Rev. Cell Biol. 5: 397.
22. Leonard W.J., et al. (1984) Nature 311: 626.
23. Nikaido T., et al. (1984) Nature 311: 631.
24. Cosman D., et al. (1984) Nature 312: 768.
25. Hatakeyama M., et al. (1989) Science 244: 551.
26. Hatakeyama M., et al. (1991) Science 252: 1523.
27. Minami Y., et al. (1993) Annu. Rev. Immunol. 11: 245.
28. Takeshita T., et al. (1992) Science 257: 379.
29. Hatakeyama M., et al. (1985) Nature 318: 467.
30. Zurawsky S.M., et al. (1990) EMBO J. 9: 3899.
31. Taniguchi T. and Y. Minami. (1993) Cell 73: 5.
32. Waldmann T.A. (1991) J. Biol. Chem. 266: 2681.
33. Waldmann T.A. (1993) Immunol. Today 14: 264.
34. Voss S.D., et al. (1994) Blood 83: 626.
35. Leonard W.J., et al. (1994) Immunol. Rev. 138: 61.
36. Leonard W.J., et al. (1994) Curr. Opin. Immunol. 6: 631.
37. Fernandez-Botran R. (1991) FASEB J. 5: 2567.
38. Rubin L.A., et al. (1985) Hybridoma 4: 91.
39. Honda M., et al. (1990) J. Immunol. 145: 4131.
40. Rosenberg S.A., et al. (1986) Science 233: 1318.
41. Rosenberg S.A., et al. (1987) N. Engl. J. Med. 316: 889.
42. Rosenberg S.A., et al. (1988) Ann. Surg. 208: 121.
43. Yang S.C., et al. (1991) Cancer Res. 51: 3669.
44. Kirkman R.A., et al. (1985) J. Exp. Med. 162: 358.
45. Kelley V.J., et al. (1988) J. Immunol. 140: 59.

